Tuesday, 19 Mar 2019

You are here

Best of 2017: Are ANA Tests Unreliable?

Pisetsky and colleagues have reported in the Annals of Rheumatic Disease that ANA tests done on established SLE patients may yield surprisingly disparate results.

While ANA negative lupus was a problem of old assays and the loss of ANA positivity may be seen with chronicity or age, most rheumatologists believe that ANA positivity is an absolute requirement for the diagnosis of systemic lupus erythematosus (SLE).

Researchers studied 103 patients with established SLE using three different immunofluorescence assays (IFA) for ANA determination. ANA determinations were also performed by an ELISA and bead-based multiplex assay.

With the IFA kits, ANA negativity was found in 4.9%–22.3% of serum samples. Moreover, the ELISA and multiplex assays found 11.7 to 13.6% seronegativity as well.

Patients with positive assays were more likely to have historic anti–double-stranded DNA positivity and low complement levels.

These findings raise numerous questions including whether these 5-22% of ANA seronegative lupus patients should be considered for clinical trials or managed differently.

Might these findings parallel that seen in rheumatoid arthritis with seronegative and seropositive populations?  While the overlap in treatment and outcomes is considerable, seropositivity (especially for ACPA) has the advantage of homogenizing the population under study.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Cyclosporin and IVIG Effective in Kawasaki's Disease

A Lancet study has shown that adding cyclosporin to intravenous immunoglobulin (IVIG) Kawasaki disease patients, who were predicted to be resistant to IVIG, was both safe and effective in averting severe coronary artery outcomes.

Brazilian Guidelines for Systemic Autoimmune Myopathies

The Myopathy Committee of the Brazilian Society of Rheumatology (BSR) has put forward recommendations for the management of patients with systemic autoimmune myopathies (SAM).

The challenge has been that there is a paucity of effective controlled clinical trials, and hence, glucocorticoids (GC) have played a first-line and prominent role in the treatment of SAM.

EULAR Consensus Guidelines for Juvenile Localized Scleroderma

A EULAR international committee of 15 experts in pediatric rheumatology have established consensus-based recommendations for the management of juvenile localised scleroderma (JLS).

JLS is an uncommon disorder that is commonly seen by pediatric and adult rheumatologists. Evidence-based guidelines are sparse and management is mostly based on physicians’ experience.

2018 Swedish Guidelines for Giant Cell Arteritis Treatment

The Swedish Society of Rheumatology has developed evidence-based guidelines for the management of giant cell arteritis (GCA) with a focus on the appropriate use of corticosteroids and tocilizumab. 

Congenital Heart Block: Dangers Ahead

Children of autoantibody-positive mothers who were born with congenital heart block were at high risk for developing later cardiovascular and autoimmune disorders, as were their siblings, Swedish researchers reported.